Sublimity Therapeutics is a specialty pharma company with offices in Dublin, Ireland and Solana Beach, California focused on therapies for gastrointestinal and immunological diseases. Its lead product, STI-0529 (formerly CyCol®), is an orally delivered soluble formulation of cyclosporine designed to bypass upper GI absorption and target drug release in the colon. A prior Phase 2a study in more than 100 patients with mild to moderate ulcerative colitis showed STI-0529 to be safe and well tolerated. The company completed a US$64 million financing to fund further clinical development and intends to initiate a global Phase 2b dose‑ranging study in moderate to severe ulcerative colitis. Sublimity has a strategic collaboration with Dr. Falk Pharma that included an upfront equity investment and calls for development funding, milestone payments and tiered double‑digit royalties in Europe. Management changes accompanied the financing, with appointments of Anthony J. Giovinazzo as Executive Chairman, Dr. Albert Agro as CEO, and Andrew Williams as CFO.

Total raised

$64M

Funding rounds

1

Latest round

Equity

Latest activity

May 2018